BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 14534738)

  • 1. Aphidicolin decreases ex vivo resistance to cytosine arabinoside in childhood acute leukaemia.
    Sargent JM; Williamson CJ; Hubeek I; Elgie AW; Taylor CG; Den Boer ML; Peters GJ; Kaspers GL
    Oncol Rep; 2003; 10(6):2027-31. PubMed ID: 14534738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML.
    Sargent JM; Elgie AW; Williamson CJ; Lewandowicz GM; Taylor CG
    Br J Cancer; 2001 Mar; 84(5):680-5. PubMed ID: 11237390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aphidicolin markedly increases the in vitro sensitivity to ara-C of blast cells from patients with AML.
    Sargent JM; Elgie AW; Williamson CJ; Taylor CG
    Adv Exp Med Biol; 1999; 457():567-70. PubMed ID: 10500835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia.
    Hubeek I; Peters GJ; Broekhuizen AJ; Sargent J; Gibson BE; Creutzig U; Kaspers GJ
    Br J Haematol; 2005 Oct; 131(2):219-22. PubMed ID: 16197453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
    Boos J; Hohenlöchter B; Schulze-Westhoff P; Schiller M; Zimmermann M; Creutzig U; Ritter J; Jurgens H
    Med Pediatr Oncol; 1996 Jun; 26(6):397-404. PubMed ID: 8614376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
    Fazlina N; Maha A; Jamal R; Zarina AL; Cheong SK; Hamidah H; Ainoon O; Zulkifli SZ; Hamidah NH
    Hematology; 2007 Feb; 12(1):33-7. PubMed ID: 17364990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
    Schiller M; Hohenlöchter B; Schulze-Westhoff P; Zimmermann M; Ritter J; Jürgens H; Boos J
    Klin Padiatr; 1996; 208(4):151-9. PubMed ID: 8926681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of DNA ligase I by 1-beta-D-arabinosylcytosine and aphidicolin in MiaPaCa human pancreatic cancer cells.
    Sun D; Urrabaz R; Buzello C; Nguyen M
    Exp Cell Res; 2002 Oct; 280(1):90-6. PubMed ID: 12372342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo drug resistance profile in childhood acute myelogenous leukemia: no drug is more effective in comparison to acute lymphoblastic leukemia.
    Styczynski J; Wysocki M; Debski R; Juraszewska E; Malinowska I; Stanczak E; Ploszynska A; Stefaniak J; Mazur B; Szczepanski T
    Leuk Lymphoma; 2002 Sep; 43(9):1843-8. PubMed ID: 12685842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydrocortisone in culture protects the blast cells in acute myeloblastic leukemia from the lethal effects of cytosine arabinoside.
    Yang GS; Wang C; Minkin S; Minden MD; McCulloch EA
    J Cell Physiol; 1991 Jul; 148(1):60-7. PubMed ID: 1860896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
    Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Janka-Schaub GE; van Zantwijk CH; Huismans DR; de Vries E; Rots MG; Peters GJ; Jansen G; Creutzig U; Veerman AJ
    Blood; 2002 Jan; 99(1):245-51. PubMed ID: 11756178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
    Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
    Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide.
    Estlin EJ; Yule SM; Lowis SP
    Cancer Treat Rev; 2001 Dec; 27(6):339-50. PubMed ID: 11908927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia.
    Yang GS; Minden MD; McCulloch EA
    Leukemia; 1994 Dec; 8(12):2065-75. PubMed ID: 7807996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of blast cell survival and proliferation to chemotherapy resistance in AML.
    Nørgaard JM; Langkjer ST; Palshof T; Clausen N; Pedersen B; Hokland P
    Br J Haematol; 1996 Jun; 93(4):888-97. PubMed ID: 8703822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo activity of thalidomide in childhood acute leukemia.
    Styczynski J; Czyzewski K; Wysocki M
    Leuk Lymphoma; 2006 Jun; 47(6):1123-8. PubMed ID: 16840205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA; Laug WE; Sausville EA; Avramis VI
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytosine arabinoside (ara-C) and cis-dichlorodiammineplatinum II (cisplatin) alone and in combination: effects on acute myeloblastic leukemia blast cells in culture and in vivo.
    Wang YF; Curtis JE; Lipton J; Minkin S; McCulloch EA
    Leukemia; 1991 Jun; 5(6):522-7. PubMed ID: 1711641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
    Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
    J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sensitivity to cytosine arabinoside of the blast progenitors of acute myeloblastic leukemia.
    Nara N; Curtis JE; Senn JS; Tritchler DL; McCulloch EA
    Blood; 1986 Mar; 67(3):762-9. PubMed ID: 3456247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.